Hancock 2

Manufactured by Medtronic

Sourced in United States, Brazil, Italy

The Hancock II is a prosthetic heart valve manufactured by Medtronic. It is designed to replace a patient's diseased or damaged heart valve. The Hancock II valve is constructed with bovine pericardial tissue and is available in various sizes to accommodate different patient needs.

Automatically generated - may contain errors

Lab products found in correlation

Perimount magna, by Edwards Lifesciences (2 mentions) Corevalve, by Medtronic (2 mentions) Carpentier edwards perimount, by Edwards Lifesciences (1 mentions) Sapien xt, by Edwards Lifesciences (1 mentions) Sapien 3, by Edwards Lifesciences (1 mentions) Perimount magna ease, by Edwards Lifesciences (1 mentions) Trifecta, by Abbott (1 mentions) Magna ease, by Edwards Lifesciences (1 mentions) Sapien valve, by Edwards Lifesciences (1 mentions)

Spelling variants of this product

Hancock II porcine bioprosthesis (2 citations) Hancock II T505 (2 citations)

5 protocols using hancock 2

Comparative Analysis of Pericardial and Porcine Bioprostheses

Check if the same lab product or an alternative is used in the 5 most similar protocols

Pericardial valves included in the analysis were Carpentier-Edwards Perimount and Perimount Magna (Edwards Lifesciences, Irvine, CA, USA), Sorin Mitroflow and Soprano (LivaNova, London, UK) and St. Jude Trifecta (Abbott, Chicago, IL, USA). Porcine valves included were St. Jude Biocor and Epic Supra (Abbott), Medtronic Hancock II, Hancock II Ultra and Mosaic (Medtronic, Minneapolis, MN, USA). Carpentier-Edwards Perimount Magna (76.8%) and Medtronic Hancock II (56.6%) were the mostly commonly used bioprostheses in the Pericardial and the Porcine groups, respectively. Details on the bioprosthetic valves used are summarized in Supplementary Table 1.

Shin H.J., Kim W.K., Kim J.K., Kim J.B., Jung S.H., Choo S.J., Chung C.H, & Lee J.W. (2021). Pericardial Versus Porcine Valves for Surgical Aortic Valve Replacement. Korean Circulation Journal, 52(2), 136-146.

+ Open protocol

+ Expand

Mitral Valve Replacement Techniques

Check if the same lab product or an alternative is used in the 5 most similar protocols

All operations were performed under aortobicaval cannulation, moderate systemic hypothermia, and cold cardioplegic arrest through median sternotomy. Mitral valve replacement was performed using the everted mattress sutures buttress reinforced with polytetrafluoroethylene as a pledget or a tubule. Use of simple interrupted sutures or continuous suture technique was avoided. Three types of mechanical valves (n ¼ 1,024: Carbomedics; Sulzer Carbomedics Inc, Austin, TX, in 444 patients; On-X valve; On-X Life Technology Inc, Austin, TX, in 392 patients; and St. Jude valve; St. Jude Medical Inc, Minneapolis, MN, in 188 patients) and two types of bioprostheses (n ¼ 165: Carpentier-Edwards Perimount; Edwards Lifesciences LLC, Irvine, CA, in 126 patients; and Hancock II; Medtronic Inc, Minneapolis, MN, in 39 patients) were used in most patients (1,189 of 1,202). Six hundred eighty-four patients underwent concomitant procedures including aortic valve surgery (n ¼ 420), tricuspid valve operation (n ¼ 335), and arrhythmia surgery (n ¼ 410; Table 2). Mean cardiopulmonary bypass and aortic cross-clamp times were 178 AE 73 min and 117 AE 49 min, respectively. Patients underwent first time (n ¼ 872), redo (n ¼ 322), or second redo MVR (n ¼ 8).

Hwang H.Y., Choi J.W., Kim H.K., Kim K.H., Kim K.B, & Ahn H. (2015). Paravalvular Leak After Mitral Valve Replacement: 20-Year Follow-Up. The Annals of thoracic surgery, 100(4).

+ Open protocol

+ Expand

Complex Tetralogy of Fallot Repair

Check if the same lab product or an alternative is used in the 5 most similar protocols

All patients, independently from the chosen strategy, were approached via a median sternotomy, cardiopulmonary bypass (CPB) and bicaval cannulation. Patients were cooled to temperatures of 25.7±1.9°C. After the initiation of CPB and administration of crystalloid cardioplegia, the pulmonary arteries were excised from the truncal vessel. The resulting defect was closed primarily or with a bovine pericardial patch. Right ventricle-to-pulmonary artery (RVPA) continuity was reconstructed with a valveless or valved conduit (n = 5 Contegra 12 mm; Medtronic, Inc, Minneapolis, MN, USA; n = 1 Labcor 11 mm; Labcor Laboratórios-Ltda, Brazil; n = 1 Hancock-II 12 mm; Medtronic, Inc; n = 2 Dacron valveless prosthesis; n = 1 decellularized homograft ‘Espoir’ 9 mm; Corlife OHG, Hannover, Germany) and in 1 patient with a direct RVPA anastomosis. The VSD was closed with a patch (n = 1 Dacron, n = 10 bovine pericardium). Additional procedures such as patent foramen ovale/ASD closure (n = 7), VSD enlargement (n = 1), persistent left superior vena cava ligature (n = 1) and left pulmonary artery plasty (n = 1) were also performed.

Cuomo M., Purbojo A., Blumauer R., Schöber M., Wällisch W., Dittrich S, & Cesnjevar R.A. (2021). Repair of common arterial trunk: palliation and delayed correction as a viable alternative strategy in selected patients. European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery, 62(1), ezab455.

+ Open protocol

+ Expand

Minimally Invasive Aortic Valve Replacement

Check if the same lab product or an alternative is used in the 5 most similar protocols

Table 1 summarizes the preoperative patient variables before and after PS matching. After matching, we found 177 triples not differing in terms of their preoperative risk profile. According to the z-differences in Table 1 and the Q-Q-plots in Figure 1, balance of risk factors dramatically improved after PS matching. In the matched sample, balance is better than in a randomized trial and very close to a perfectly matched PS analysis.
Patients undergoing MIC-AVR received stented prostheses (Perimount Magna, Edwards Lifesciences, Irvine, Calif; 131/177, 74.0%, Perimount Magna Ease, Edwards Lifesciences; 25/177, 14.1%, Hancock II, Medtronic, Minneapolis, Minn; 5/177, 2.8%, Trifecta, St Jude Medical Inc, St Paul, Minn; 14/177, 7.9%) or sutureless prostheses (Perceval, Sorin/LivaNova Group, Saluggia, Italy; 2/177, 1.1%). In the TA-TAVI group, the implanted prostheses were Sapien XT (Edwards Lifesciences; 74/177, 41.8%), Sapien 3 (Edwards Lifesciences; 57/ 177, 32.2%), or Accurate TA (Symetis, Lausanne, Switzerland; 46/ 177, 26.0%). In the TF-TAVI group, the implanted prostheses were Cor-eValve (Medtronic, Minneapolis, Minn; 99/177, 55.9%), Sapien XT (28/ 177, 15.8%), Sapien 3 (26/177, 14.7%), Accurate TF neo (4/177, 2.3%), or Direct Flow (Direct Flow Medical Inc, Santa Rosa, Calif; 20/177, 11.3%).

Furukawa N., Kuss O., Emmel E., Scholtz S., Scholtz W., Fujita B., Ensminger S., Gummert J.F, & Börgermann J. (2018). Minimally invasive versus transapical versus transfemoral aortic valve implantation: A one-to-one-to-one propensity score-matched analysis. The Journal of thoracic and cardiovascular surgery, 156(5).

+ Open protocol

+ Expand

Surgical Valve Selection in Transcatheter Aortic Valve Implantation

Check if the same lab product or an alternative is used in the 5 most similar protocols

In the Translink study, the choice of BHV type was left to the decision of the cardio-surgical team of each center. Patients were implanted with the most frequently implanted BHVs worldwide: two types of surgical porcine valves: Mosaic or Hancock II (Medtronic); 6 different surgical bovine pericardium valves: Perimount Carpentier–Edwards (Edwards Lifesciences), Magna Ease (Edwards Lifesciences), Trifecta (St Jude Medical), Perceval or SOLO bioprostheses (Sorin Biomedica Cardio) and the Mitroflow PRT valve (Sorin Biomedica Cardio); one surgical equine valve: 3F Valve Enable (Medtronic) and two percutaneous pericardium valves (TAVI): CoreValve (porcine pericardium; Medtronic) and SAPIEN valve (bovine pericardium; Edwards Lifesciences). The operating techniques and surgical valve model selection were left to the operating surgeon’s discretion. The distribution of types of implanted biological prostheses in groups B1/B2 is detailed in Fig. 1b.

Senage T., Paul A., Le Tourneau T., Fellah-Hebia I., Vadori M., Bashir S., Galiñanes M., Bottio T., Gerosa G., Evangelista A., Badano L.P., Nassi A., Costa C., Cesare G., Manji R.A., Cueff de Monchy C., Piriou N., Capoulade R., Serfaty J.M., Guimbretière G., Dantan E., Ruiz-Majoral A., Coste du Fou G., Leviatan Ben-Arye S., Govani L., Yehuda S., Bachar Abramovitch S., Amon R., Reuven E.M., Atiya-Nasagi Y., Yu H., Iop L., Casós K., Kuguel S.G., Blasco-Lucas A., Permanyer E., Sbraga F., Llatjós R., Moreno-Gonzalez G., Sánchez-Martínez M., Breimer M.E., Holgersson J., Teneberg S., Pascual-Gilabert M., Nonell-Canals A., Takeuchi Y., Chen X., Mañez R., Roussel J.C., Soulillou J.P., Cozzi E, & Padler-Karavani V. (2022). The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration. Nature Medicine, 28(2), 283-294.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!